Susan Altschuller
CFO & Principal Accounting OfficerDr. Susan Altschuller, Ph.D., M.B.A., is Chief Financial Officer of Climb Bio, Inc. from October 2025 and its Principal Accounting Officer since April 30, 2026. She served as Chief Financial Officer of DRAGONFLY Therapeutics, Inc. from August 2024 to December 2024. She served as an Independent Director at Mural Oncology plc since November 15, 2023 until September 1, 2024. She joined ImmunoGen in July 20, 2020 and served as its Senior Vice President and Chief Financial Officer since July 20, 2020. She served as Chief Financial Officer at Cerevel Therapeutics Holdings, Inc. since May 15, 2023 until August 2024. She serves as a Director of Vestaron Corporation. She served as Vice President of Investor Relations at Alexion Pharmaceuticals, Inc. She served as an Executive Director of Investor Relations at Bioverativ Inc. She served as Head-Investor Relations of Biogen, Inc. She started as Head of Investor Relations at Alexion Pharmaceuticals before moving to Head of Enterprise Finance. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all Investor-related activities for the launch of the Biogen spin-off. She is a founding board member of the HNRNP Family Foundation. She received a BSE in Biomedical Engineering with Honors from Tulane University, a PhD in Biomedical Engineering from the Illinois Institute of Technology and an MBA from the MIT Sloan School of Management.
Positions
- Company NameClimb Bio, Inc.Stock CodeCLYMPositionCFO & Principal Accounting OfficerColleagues
- AMAoife M. BrennanCEO, President & Director
- DEDouglas Edward WilliamsIndependent Chairman of the Board
- PWPerrin WilsonChief Business Officer
- AVAdam VillaSenior Vice President of Technical Operations
- CAChandra AdamsSenior VP, General Counsel & Secretary
- AGAlexander G. CumboIndependent Director
- KCKimberlee Cobleigh DrapkinIndependent Director
- JAJudith A. DunnIndependent Director
